Immunohistochemical detection of Mdm2 and p53 in feline mammary gland tumors

Journal of Veterinary Medical Science

Volumn 68, Issue 5, 2006, Pages 421-425

  Nakano, Masatoshi ^a   Wu, Haiyan ^a   Taura, Yasuho ^a   Inoue, Makoto ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Feline mammary tumor; Mdm2; p53

Indexed keywords

PROTEIN MDM2; PROTEIN P53; TUMOR MARKER;

ADENOCARCINOMA; ADENOMA; ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CHEMISTRY; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; ADENOMA; ANIMALS; CAT DISEASES; CATS; FEMALE; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

FELIDAE;

EID: 33745005739     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.68.421     Document Type: Article

References (32)

1. Abdel-Fattah, G., Yoffe, B., Krishnan, B., Khaoustov, V. and Itani, K. 2000. MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J. Gastrointest. Surg. 4: 109-114.
2. Aikawa, H., Sato, M., Fujimura, S., Takahashi, H., Endo, C., Sakurada, A., Chen, Y., Kondo, T., Tanita, T., Matsumura, Y., Saito, Y. and Sagawa, M. 2000. Mdm2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int. J. Mol. Med. 5: 631-633.
3. Baccouche, S., Daoud, J., Frikha, M., Mokdad-Gargouri, R., Gargouri, A. and Jlidi, R. 2003. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients. Ann. New York Acad. Sci. 1010: 752-763.
4. Bankfalvi, A., Tory, K., Kemper, M., Breukelmann, D., Cubick, C., Poremba, C., Fuzesi, L., Lelle, R. J. and Bocker, W. 2000. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol. Res. Pract. 196: 489-501.
5. Borresen-Dale, A. L. 2003. Tp53 and breast cancer. Hum. Mutat. 21: 292-300.
6. Deb, S. P. 2003. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol. Cancer Res. 1: 1009-1016.
7. Endo, K., Ueda, T., Ohta, T. and Terada, T. 2000. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 20: 209-215.
8. Esrig, D., Spruck III, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A. and Cote, R. J. 1993. p53 nuclear accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 143: 1389-1397.
9. Fakharzadeh, S. S., Trusko, S. P. and George, D. L. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10: 1565-1569.
10. Gunther, T., Schneider-Stock, R., Rys, J., Niezabitowski, A. and Roessner, A. 1997. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. J. Cancer Res. Clin. Oncol. 123: 388-394.
11. Haitel, A., Wiener, H. G., Baethge, U., Marberger, M. and Susani, M. 2000. Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res. 6: 1840-1844.
12. Hayes, A. A. and Mooney, S. 1985. Feline mammary tumors. Vet. Clin. North Am. Small Anim. Pract. 15: 513-520.
13. Kasper, H. U., Schneider-Stock, R., Mellin, W., Gunther, T. and Roessner, A. 1999. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Pathol. Res. Pract. 195: 815-820.
14. Lambkin, H. A., Mothersill, C. M. and Kelehan, P. 1994. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J. Pathol. 172: 13-18.
15. Lee, C. H. and Kweon, O. K. 2002. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J. Vet. Sci. 3: 321-325.
16. Leite, K. R., Franco, M. F., Srougi, M., Nesrallah, L. J., Nesrallah, A., Bevilacqua, R. G., Darini, E., Carvalho, C. M., Meirelles, M. I., Santana, I. and Camara-Lopes, L. H. 2001. Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. 14: 428-436.
17. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
18. Lukas, J., Gao, D. Q., Keshmeshian, M., Wen, W. H., Tsao-Wei, D., Rosenberg, S. and Press, M. F. 2001. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 61: 3212-3219.
19. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B. and Kouzarides, T. 1995. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature (Lond.) 375: 691-694.
20. Misdorp, W., Else, R. W., Hellmen, E. and Lipscomb, T. P. 1999. Histological Classification of Mammary Tumors of the Dog and Cat. pp. 1-59. In: World Health Organization International Histological Classification of tumors of Domestic Animals, 2nd series, vol. 7, Armed Forces Institute of Pathology, Washington.
21. Moll, U. M. and Petrenko, O. 2003. The MDM2-p53 interaction. Mol. Cancer Res. 1: 1001-1008.
22. Murakami, Y., Tateyama, S., Rungsipipat, A., Uchida, K. and Yamaguchi, R. 2000. Immunohistochemical analysis of cyclin A, cyclin D1 and p53 in mammary tumors, squamous cell carcinomas and basal cell tumors of dogs and cats. J. Vet. Med. Sci. 62: 743-750.
23. Muto, T., Wakui, S., Takahashi, H., Maekawa, S., Masaoka, T., Ushigome, S. and Furusato, M. 2000. p53 gene mutations occurring in spontaneous benign and malignant mammary tumors of the dog. Vet. Pathol. 37: 248-253.
24. Nakano, M., Taura, Y. and Inoue, M. 2005. Protein expression of Mdm2 and p53 in hyperplastic and neoplastic lesions of the canine circumanal gland. J. Comp. Pathol. 132: 27-32.
25. Nasir, L., Rutteman, G. R., Reid, S. W., Schulze, C. and Argyle, D. J. 2001. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Cancer Lett. 174: 83-89.
26. Schoniger-Hekele, M., Hanel, S., Wrba, F. and Muller, C. 2005. Hepatocellular carcinoma-survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int. 25: 62-69.
27. Setoguchi, A., Okuda, M., Nishida, E., Yazawa, M., Ishizaka, T., Hong, S. H., Hisasue, M., Nishimura, R., Sasaki, N., Yoshikawa, Y., Masuda, K., Ohno, K. and Tsujimoto, H. 2001. Results of hyperamplification of centrosomes in naturally developing tumors of dogs. Am. J. Vet. Res. 62: 1134-1141.
28. Sun, P., Dong, P., Dai, K., Hannon, G. J. and Beach, D. 1998. p53-independent role of MDM2 in TGF-beta1 resistance. Science 282: 2270-2272.
29. Uchida, T., Minei, S., Gao, J. P., Wang, C., Satoh, T. and Baba, S. 2002. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol. Rep. 9: 253-259.
30. Woods, D. B. and Vousden, K. H. 2001. Regulation of p53 function. Exp. Cell Res. 264: 56-66.
31. Wu, L. and Levine, A. J. 1997. Differential regulation of the p21/WAF1 and MDM2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the MDM2 gene. Mol. Med. 3: 441-451.
32. Xiao, Z., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R. and Livingston, D. M. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (Lond.) 375: 694-698.